TITLE

Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer

AUTHOR(S)
Osmonov, Daniar K.; Aksenov, Alexey V.; Boller, Annkathrin; Kalz, Almut; Heimann, Diana; Janssen, Isa; Jünemann, Klaus-Peter
PUB. DATE
January 2014
SOURCE
Advances in Urology;2014, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Treatment of patients with a biochemical recurrence (BCR) of prostate cancer (PCa) is generally difficult and without valid treatment options. Since 2004 we have been developing therapeutic possibilities for these patients. Methods. We retrospectively analyzed a cohort of 41 patients with a BCR of PCa and a mean followup of 40.3 ± 20.8 months. Group 1 (n = 10): salvage radical prostatectomy (sRP) with SePLND (salvage extended pelvic lymph nodes dissection) (initial treatment: combined brachytherapy). Group 2 (n = 22): SePLND (initial treatment: radical prostatectomy (RP)). Group 3 (n = 9): SePLND (initial treatment: RP and adjuvant radiation therapy (RT)). We observed PSA, PSA-velocity, localization of LNs and LNs+, BCR-free period, and BR (biochemical response). Results. Group 1: 60% with BCR-freedom (mean 27.2 months). Group 2: 63.6% with BCR-freedom (mean 17.5 months). Group 3: 33.3% with BCR-freedom (mean 17.6 months). In total, BCR-freedom was observed in 23 of 41 patients (56.1%) after salvage surgery. 75.6% of all patients showed a BR. 765 LNs were removed and 14.8% of these were LN+. Conclusions. The BCR-free period and BR are comparable in all three groups. Sensibility to ADT can be reestablished and prolonged as a result of SePLND. Multicenter studies are needed for a reliable output.
ACCESSION #
100518607

 

Related Articles

  • Quality of life after prostate cancer treatments in patients comparable at baseline. van Tol-Geerdink, J J; Leer, J W H; van Oort, I M; van Lin, E J N T; Weijerman, P C; Vergunst, H; Witjes, J A; Stalmeier, P F M // British Journal of Cancer;5/14/2013, Vol. 108 Issue 9, p1784 

    Background:Previous studies on the effects of different prostate cancer treatments on quality of life, were confounded because patients were not comparable. This study examined treatment effects in more comparable groups.Methods:From 2008-2011, 240 patients with localised prostate cancer were...

  • Focal therapy in prostate cancer: the current situation. Jácome-Pita, F. X.; Sánchez-Salas, R.; Barret, E.; Amaruch, N.; Gonzalez-Enguita, C.; Cathelineau, X. // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    Prostate cancer is one of the most significant pathologies in the field of urology. The adoption of screening strategies and improvements in biopsies have resulted in an increase in early-stage tumour detection. Radical global therapies provide very good oncological results in localised prostate...

  • Management of Urinary Incontinence after Prostate Cancer Treatment and Urethroplasty. McCammon, Kurt A. // AUANews;Apr2015, Vol. 20 Issue 4, p8 

    The article discusses the onset of urethral stricture or bladder neck contracture complications in prostate cancer patients treated with combined brachytherapy and external beam radiation therapy. It is noted that preoperative planning is necessary given the resulting urinary incontinence rates...

  • Salvage Radical Prostatectomy after External Beam Radiation Therapy: A Systematic Review of Current Approaches. Matei, Deliu Victor; Ferro, Matteo; Jereczek-Fossa, Barbara alicja; Renne, Giuseppe; Crisan, Nicolae; Bottero, Danilo; Mazzarella, Claudia; Terracciano, Daniela; autorino, Riccardo; De Cobelli, Ottavio // Urologia Internationalis;May2015, Vol. 94 Issue 4, p373 

    Background: Radical external beam radiotherapy (EBRT) is a standard treatment for prostate cancer patients. Despite this, the rate of intraprostatic relapses after primary EBRT is still not negligible. There is no consensus on the most appropriate management of these patients after EBRT failure....

  • PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy. Gacci, M.; Serni, S.; Lapini, A.; Vittori, G.; Vignolini, G.; Nesi, G.; Carini, M. // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 1, p99 

    A 64-year-old man was treated with brachytherapy for prostate cancer. Prostate-specific antigen (PSA) nadir was achieved at 3 months, while at 24 months PSA increased to 18.7 ng ml−1. Re-biopsy and imaging revealed locally recurrent prostate carcinoma without metastasis. The patient was...

  • Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy. da Silva Franca, Carlos Antônio; Vieira, Sérgio Lannes; Carvalho, Antonio Carlos Pires; Bernabe, Antonio Jose Serrano; Penna, Antonio Belmiro Rodrigues Campbell // Radiologia Brasileira;Mar/Apr2014, Vol. 47 Issue 2, p89 

    Objective: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The...

  • Personal preferences and discordant prostate cancer treatment choice in an intervention trial of men newly diagnosed with localized prostate cancer. Bosco, Jaclyn L. F.; Halpenny, Barbara; Berry, Donna L. // Health & Quality of Life Outcomes;2012, Vol. 10 Issue 1, p123 

    Background: Men diagnosed with localized prostate cancer (LPC) can choose from multiple treatment regimens and are faced with a decision in which medical factors and personal preferences are important. The Personal Patient Profile-Prostate (P3P) is a computerized decision aid for men with LPC...

  • Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con position. Loblaw, D. Andrew // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p199 

    The author discusses how increase in the dose of radiation therapy can affect the treatment of prostate cancer. He informs that external beam radiotherapy dose when given in accurate and precise way can give better outcomes and can lower cost and also mentions that brachytherapy is a safe method...

  • The best method for dose escalation: Prostate brachytherapy. Morton, Gerard // Canadian Urological Association Journal;Jun2012, Vol. 6 Issue 3, p196 

    The author discusses the role of radiation therapy dose in the treatment of prostate cancer. He informs that external beam radiotherapy dose increases the biochemical control rate to about 10 percent in five years and also mentions that brachytherapy is a safe method of dose escalation. He...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics